Harbour BioMed signs $350m anti-PD-L1 deal with Kelun-Biotech
Chinese companies Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical have entered into an exclusive strategic collaboration for the development and commercialisation…
Harbour BioMed
-
-
Glenmark partners Harbour BioMed to develop oncology candidate in China
Glenmark Pharmaceuticals has signed an exclusive licence agreement with Harbour BioMed for the development, manufacture and commercialisation of its immuno-oncology…
